Haricef CV 500mg/125mg Tablet is a combination antibiotic formulation containing Cefuroxime 500mg and Clavulanic Acid 125mg, designed to treat a broad spectrum of bacterial infections. Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid is a beta-lactamase inhibitor that protects Cefuroxime from enzymatic degradation by beta-lactamase-producing bacteria, thereby enhancing its efficacy against resistant strains. This synergistic combination is effective against various infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media caused by susceptible organisms. Haricef CV is indicated for use in both adults and pediatric patients, with dosing adjusted according to the severity and type of infection. It is generally well-tolerated, but potential side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypersensitivity reactions in patients with beta-lactam allergy. Caution is advised in patients with a history of penicillin allergy or renal impairment. Haricef CV should be administered as prescribed, completing the full course to prevent the development of resistance and ensure optimal therapeutic outcomes.